DLK post FS LASIK

Article

Diffuse lamellar keratitis (DLK) occurs more frequently after LASIK performed with the IntraLase 15 kHz femtosecond laser than after LASIK performed with the Moria M2 microkeratome.

Diffuse lamellar keratitis (DLK) occurs more frequently after LASIK performed with the IntraLase 15 kHz femtosecond laser than after LASIK performed with the Moria M2 microkeratome, according to the results of a study published in the January issue of the Journal of Cataract and Refractive Surgery.

Raquel Gil-Carzola from VISSUM Madrid, Spain conducted a retrospective study to compare the incidence of DLK in 2,000 consecutive LASIK procedures performed with the IntraLase 15 kHz femtosecond laser (study group) or the Moria M2 microkeratome (control group). During the first week postoperatively, topical dexamethasone drops were applied eight times daily in the femtosecond group and four times daily in the mechanical microkeratome group.

The researchers found that stage 2 DLK developed in one patient from each group but that stage 3 DLK developed in four patients in the study group and in no patients in the control group (p=0.03), despite a more intensive postoperative steroid regimen.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.